Toronto Dominion Bank Buys 5,286 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Toronto Dominion Bank raised its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 9.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 60,005 shares of the biopharmaceutical company's stock after buying an additional 5,286 shares during the period. Toronto Dominion Bank owned about 0.05% of Regeneron Pharmaceuticals worth $42,743,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Pinney & Scofield Inc. bought a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter valued at about $25,000. OFI Invest Asset Management bought a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter valued at about $28,000. Rakuten Securities Inc. boosted its position in shares of Regeneron Pharmaceuticals by 62.5% during the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock valued at $28,000 after purchasing an additional 15 shares in the last quarter. Avalon Trust Co bought a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter valued at about $36,000. Finally, Crowley Wealth Management Inc. bought a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter valued at about $36,000. Institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN traded down $112.15 on Friday, hitting $493.24. 6,307,887 shares of the stock traded hands, compared to its average volume of 829,463. The business's fifty day moving average is $584.25 and its two-hundred day moving average is $666.47. Regeneron Pharmaceuticals, Inc. has a 12 month low of $485.00 and a 12 month high of $1,211.20. The firm has a market capitalization of $53.25 billion, a price-to-earnings ratio of 12.89, a PEG ratio of 2.34 and a beta of 0.43. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share for the quarter, missing the consensus estimate of $8.83 by ($0.61). Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The firm had revenue of $3.03 billion for the quarter, compared to the consensus estimate of $3.40 billion. During the same period last year, the company posted $9.55 earnings per share. Regeneron Pharmaceuticals's revenue for the quarter was down 3.7% on a year-over-year basis. As a group, equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Tuesday, May 20th will be issued a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.71%. The ex-dividend date of this dividend is Tuesday, May 20th. Regeneron Pharmaceuticals's payout ratio is currently 8.96%.

Analysts Set New Price Targets

Several research analysts have issued reports on REGN shares. BMO Capital Markets cut their price target on Regeneron Pharmaceuticals from $865.00 to $800.00 and set an "outperform" rating on the stock in a report on Wednesday, April 30th. UBS Group cut their price target on Regeneron Pharmaceuticals from $768.00 to $633.00 and set a "neutral" rating on the stock in a report on Wednesday, April 30th. Guggenheim reiterated a "buy" rating on shares of Regeneron Pharmaceuticals in a report on Friday. Truist Financial cut their price target on Regeneron Pharmaceuticals from $975.00 to $940.00 and set a "buy" rating on the stock in a report on Wednesday, April 30th. Finally, Wells Fargo & Company lowered Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and cut their price target for the stock from $700.00 to $580.00 in a report on Friday. One research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have assigned a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $874.56.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.